Abstract
Novel dihydropyrazole sulfonamide derivatives (30-56) were designed, synthesized, and evaluated for their biological activities as COX-1 and COX-2 inhibitors. In vitro biological evaluation against three human tumor cell lines revealed that most target compounds showed antiproliferative activities. Among the compounds, compound 48 exhibited the most potent and selective COX-2 inhibitor (COX-2 IC50=0.33 μM; COX-1 IC50=68.49 μM) relative to the reference drugs celecoxib (IC50=0.052 μM). Docking simulation was performed to position compound 48 into the COX-2 active site and the result showed that compound 48 could bind well at the COX-2 active site and it indicated that compound 48 could be a potent and selective COX-2 inhibitor.
Keywords:
Anticancer; COX-1/COX-2; Dihydropyrazole sulfonamide; Docking; MTT.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cyclooxygenase 1 / metabolism*
-
Cyclooxygenase 2 / metabolism*
-
Cyclooxygenase Inhibitors / chemical synthesis
-
Cyclooxygenase Inhibitors / chemistry*
-
Cyclooxygenase Inhibitors / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Design*
-
Drug Screening Assays, Antitumor
-
HeLa Cells
-
Humans
-
MCF-7 Cells
-
Models, Molecular*
-
Molecular Structure
-
Pyrazoles / chemical synthesis
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology*
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology*
Substances
-
Antineoplastic Agents
-
Cyclooxygenase Inhibitors
-
Pyrazoles
-
Sulfonamides
-
Cyclooxygenase 1
-
Cyclooxygenase 2